Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $31.93, for a total transaction of $159,650.00. The transaction was disclosed in a filing with the SEC, which is available through this link.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, September 12th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $31.86, for a total transaction of $159,300.00.
  • On Tuesday, August 8th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $30.57, for a total transaction of $152,850.00.

Genomic Health, Inc. (NASDAQ:GHDX) opened at 32.78 on Friday. The company’s market capitalization is $1.14 billion. Genomic Health, Inc. has a 52 week low of $26.37 and a 52 week high of $33.97. The firm has a 50-day moving average of $31.63 and a 200-day moving average of $31.66.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business had revenue of $85.50 million for the quarter, compared to the consensus estimate of $86.08 million. During the same period in the previous year, the firm earned ($0.18) earnings per share. The company’s revenue was up 4.3% compared to the same quarter last year. Equities analysts expect that Genomic Health, Inc. will post ($0.03) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/10/14/genomic-health-inc-ghdx-coo-sells-159650-00-in-stock.html.

Several large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in shares of Genomic Health by 3.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock valued at $516,000 after purchasing an additional 520 shares during the last quarter. State Street Corp boosted its stake in shares of Genomic Health by 2.5% in the 2nd quarter. State Street Corp now owns 517,313 shares of the medical research company’s stock valued at $16,840,000 after purchasing an additional 12,696 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Genomic Health by 26.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock valued at $12,070,000 after purchasing an additional 76,758 shares during the last quarter. Numeric Investors LLC boosted its stake in shares of Genomic Health by 53.6% in the 2nd quarter. Numeric Investors LLC now owns 89,999 shares of the medical research company’s stock valued at $2,929,000 after purchasing an additional 31,423 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in shares of Genomic Health by 18.5% in the 2nd quarter. Voya Investment Management LLC now owns 8,622 shares of the medical research company’s stock valued at $281,000 after purchasing an additional 1,344 shares during the last quarter. 88.90% of the stock is currently owned by institutional investors.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday. Cowen and Company reaffirmed a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, September 1st. Jefferies Group LLC reaffirmed a “hold” rating and issued a $33.00 price objective on shares of Genomic Health in a research note on Thursday, September 14th. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Genomic Health in a research note on Wednesday, September 27th. Finally, BidaskClub cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $31.83.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.